CClinicalTrials.gg
CompletedNCT03056287Updated May 14, 2025Results posted

Exercise and Brain Stimulation for Post-stroke Depression

An interventional study of Aerobic exercise and Repetitive transcranial magnetic stimulation in Stroke, sponsored by Medical University of South Carolina. Completed at 1 site in United States. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jan 2016, registered Feb 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
50 Years to 70 Years
Sex
All
01

Study summary

This project will assess the effects of aerobic exercise training (AET), repetitive transcranial magnetic stimulation (rTMS) or their combination on depressive severity as well as locomotor function in persons with post-stroke depression (PSD). Both AET and rTMS are established stand-alone treatments for non-stroke related depression, though neither has been adequately studied post-stroke. Furthermore, substantive research indicates that AET improves post-stroke locomotor function, thus offering a novel approach for treating PSD as well as an established vehicle to study the effects of PSD on response to rehabilitation.

The purpose of this project is to determine the impact of AET, rTMS and their combination (AET+rTMS) treatments on post-stroke depressive symptoms and locomotor function so as to guide the development of a future clinical trial. A total of 40 depressed post-stroke subjects will be randomly assigned to one of four groups 1) AET; 2) rTMS; 3) combined AET and rTMS (AET+rTMS) or 4) control (sham rTMS) group (n=10 per condition; equally distributed with mild and moderate MDD). Further, an additional 10 non-depressed post-stroke subjects will complete 8 weeks of AET so as to allow us to determine the effects of PSD on response to training (Aim 2). Training (AET, rTMS and AET+rTMS) will take place over an 8-week period, three times per week on non-consecutive days. Measures of depression (HRSD17) as well as self-selected walking speed (SSWS) will be performed prior to the initial treatment session of each week as well as 8 weeks following cessation of treatment. Additional measures of locomotor function (walking endurance and amount of daily community stepping) will be assessed prior to training (pre), following 4 weeks of training (mid), upon completion of 8 weeks of training (post) as well as 8 weeks following cessation of training (follow-up), allowing determination of the efficacy (and persistence) of training on these outcomes.

02

Conditions studied

  • Stroke

Browse trials for

03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 23 is below the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Medical University of South Carolina is the lead sponsor of 852 studies on the registry; 165 are open to participants now.

Of its 128 completed or terminated interventional studies of FDA-regulated products, 101 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age 50-70
  2. stroke within the past 6 to 60 months,
  3. major depressive disorder (PHQ-9 > 10) and diagnosed using the Structured Clinical Interview for Depression (SCID) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV),
  4. residual paresis in the lower extremity (Fugl-Meyer LE motor score \<34),
  5. ability to walk without assistance and without an AFO on the treadmill ≥ 30 seconds at speeds ranging from 0.2-0.8 m/s,
  6. no antidepressant medications or clinically able to discontinue medications,
  7. HRSD question #9 regarding suicide \<2,
  8. provision of informed consent. In addition, all subjects who meet criteria for the training portion must complete an exercise tolerance test and be cleared for participation by the study cardiologist.

Exclusion criteria

Exclusion Criteria:

  1. Unable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking;
  2. history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during ADL's;
  3. History of oxygen dependence;
  4. Preexisting neurological disorders, dementia or previous stroke;
  5. History of major head trauma;
  6. Legal blindness or severe visual impairment;
  7. history of psychosis or other Axis I disorder that is primary;
  8. Life expectancy \<1 yr.;
  9. Severe arthritis or other problems that limit passive range of motion;
  10. History of DVT or pulmonary embolism within 6 months;
  11. Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions;
  12. Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest;
  13. attempt of suicide in the last 2 years or at suicidal risk assessed by SCID interview;
  14. Previous or current enrollment in a clinical trial to enhance motor recovery;
  15. currently exercising ≥ 2 times per week (≥20 minutes);
  16. Presence of non-MR compatible implants, pregnancy or severe claustrophobia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Aerobic Exercise

    Treadmill aerobic exercise

    Behavioral: Aerobic exercise

  • Experimental
    rTMS

    repetitive transcranial magnetic stimulation

    Other: Repetitive transcranial magnetic stimulation

  • Experimental
    AET+rTMS

    Combined aerobic exercise and rTMS

    Behavioral: Aerobic exercise · Other: Repetitive transcranial magnetic stimulation

  • Sham comparator
    Sham

    Sham rTMS

    Other: Repetitive transcranial magnetic stimulation

Interventions

  • BehavioralAerobic exercise

    treadmill aerobic exercise; 3 sessions per week, 40 minutes per session

  • OtherRepetitive transcranial magnetic stimulation

    Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.

    Also known as: rTMS

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Post Training in Hamilton Rating Scale for Depression

    The Hamilton Rating Scale for Depression is a clinician-administered depression assessment scale containing 17 items pertaining to symptoms of depression experienced over the past week. A total score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a total score of 20 or higher indicates at least moderate severity depression. Score range 0-58. Higher total scores indicate higher levels of depression, while a score of 0 would indicate no depressive symptoms.

    Time frame: assessed at baseline and weekly throughout the 8 week intervention. Change from baseline to week 8 reported as primary outcome

Secondary outcomes

  1. Change From Baseline to Week 8 in Self-selected Walking Speed

    Time frame: assessed at baseline as well as weekly throughout the 8 week intervention. Change from baseline to week 8 reported as outcome

07

Results

Posted May 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneAerobic ExerciserTMSAET+rTMSSham
Started4667
Completed4556
Not completed0111
Withdrew: Withdrawal by subject0100
Withdrew: Move out of area0011

Outcome measures

PrimaryChange From Baseline to Post Training in Hamilton Rating Scale for Depression

The Hamilton Rating Scale for Depression is a clinician-administered depression assessment scale containing 17 items pertaining to symptoms of depression experienced over the past week. A total score of 0-7 is generally accepted to be within the normal range (or in clinical remission), while a total score of 20 or higher indicates at least moderate severity depression. Score range 0-58. Higher total scores indicate higher levels of depression, while a score of 0 would indicate no depressive symptoms.

Time frame:
assessed at baseline and weekly throughout the 8 week intervention. Change from baseline to week 8 reported as primary outcome
Reported as:
Mean · units on a scale
Change From Baseline to Post Training in Hamilton Rating Scale for Depression
units on a scaleAerobic ExerciserTMSAET+rTMSSham
Change From Baseline to Post Training in Hamilton Rating Scale for Depression-2.75 ± 4.5-7.5 ± 5.46-7.83 ± 4.49-2.29 ± 2.63
SecondaryChange From Baseline to Week 8 in Self-selected Walking Speed
Time frame:
assessed at baseline as well as weekly throughout the 8 week intervention. Change from baseline to week 8 reported as outcome
Reported as:
Mean · centimeters per second
Change From Baseline to Week 8 in Self-selected Walking Speed
centimeters per secondAerobic ExerciserTMSAET+rTMSSham
Change From Baseline to Week 8 in Self-selected Walking Speed8.2 ± 9.527.7 ± 15.4330.65 ± 20.242.19 ± 15.04

Adverse events

Collected over Throughout the 8 week intervention as well as during an 8 week follow-up period. Collected over a total of weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aerobic Exercise0/4 (0%)0/4 (0%)1/4 (25%)
rTMS0/6 (0%)0/6 (0%)0/6 (0%)
AET+rTMS0/6 (0%)0/6 (0%)1/6 (16.7%)
Sham0/7 (0%)0/7 (0%)0/7 (0%)
Most frequent other events
Most frequent other events
EventAerobic ExerciserTMSAET+rTMSSham
fallMusculoskeletal and connective tissue disorders1/40/61/60/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Aerobic ExerciserTMSAET+rTMSShamTotal
<=18 years00000
Between 18 and 65 years434617
>=65 years03216
Sex: Female, Male
Sex: Female, Male(Participants)Aerobic ExerciserTMSAET+rTMSShamTotal
Female343414
Male12339
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aerobic ExerciserTMSAET+rTMSShamTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American313310
White153413
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Aerobic ExerciserTMSAET+rTMSShamTotal
United States466723
08

Study locations

1 site
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 28, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03056287
Lead sponsor
Medical University of South Carolina
Responsible party
Sponsor
First posted
Feb 17, 2017
Start date
Jan 1, 2016
Primary completion
Dec 31, 2019
Completion
Dec 31, 2019
Results posted
May 14, 2025
Last update
May 14, 2025

Study contacts

Chris M Gregory, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion